

NERLYNX (neratinib)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

- 1. Early stage breast cancer (Stage 1 − 3c)
 - a. Used for extended adjuvant treatment
 - b. Previously treated with trastuzumab
- 2. Advanced or Metastatic breast cancer (Stage 4)
 - a. Used in combination with capecitabine
 - Patient has previously received two or more anti-HER2 based regimens

AND ALL of the following:

- 1. Human epidermal growth factor receptor 2 (HER2)-positive
- Prescriber agrees to manage diarrhea through **ONE** of the following:
 - a. Nerlynx dose escalation with antidiarrheal treatment as needed
 - Antidiarrheal prophylaxis starting with the first dose of Nerlynx and continuing during the first 56 days of treatment and as needed thereafter

Prior - Approval Limits

Quantity 540 tablets per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements

NO renewal for early stage breast cancer

Age 18 years of age or older

Diagnosis

Patient must have the following:

Advanced or metastatic breast cancer (Stage 4)



NERLYNX (neratinib)

AND ALL of the following:

- 1. Used in combination with capecitabine
- 2. NO disease progression or unacceptable toxicity

Prior - Approval Renewal Limits

Quantity 540 tablets per 90 days

Duration 12 months

NO renewal for early stage breast cancer